Publication | Open Access

A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)

OncologyHeat ShockMedicinePathologyImmune Checkpoint InhibitorCancer TreatmentSecond-line TherapyPharmacologyRadiation OncologyLung Cancer